Akari Therapeutics (NASDAQ:AKTX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Free Report) in a research report sent to investors on Monday. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Akari Therapeutics Price Performance Akari Therapeutics stock opened at $3.60 on Monday. Akari Therapeutics has a twelve month low of $2.81 and a […]

Leave a Reply

Your email address will not be published.

Previous post Editorial: Standing up, speaking out against Hamas terror
Next post Startek (NYSE:SRT) Coverage Initiated by Analysts at StockNews.com